Media Reporting of Practice-Changing Clinical Trials in Oncology: A North American Perspective

被引:3
|
作者
Andrew, Peter [1 ]
Vickers, Michael M. [1 ]
O'Connor, Stephen [2 ]
Valdes, Mario [3 ]
Tang, Patricia A. [4 ]
机构
[1] Univ Ottawa, Div Med Oncol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada
[2] City Univ London, London EC1V 0HB, England
[3] Grand River Reg Canc Ctr, Kitchener, ON, Canada
[4] Univ Calgary, Dept Med Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada
来源
ONCOLOGIST | 2016年 / 21卷 / 03期
关键词
Clinical trials; Journalism; Neoplasms; Social media; TRASTUZUMAB PLUS DOCETAXEL; CANCER-PATIENTS; GOOGLE-SCHOLAR; NEWS MEDIA; DOUBLE-BLIND; INTERNET USE; TWITTER USE; PHASE-III; CHEMOTHERAPY; CITATIONS;
D O I
10.1634/theoncologist.2015-0056
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Media reporting of clinical trials impacts patient-oncologist interactions. We sought to characterize the accuracy of media and Internet reporting of practice-changing clinical trials in oncology. Materials and Methods. The first media articles referencing 17 practice-changing clinical trials were collected from 4 media outlets: newspapers, cable news, cancer websites, and industry websites. Measured outcomes were media reporting score, social media score, and academic citation score. The media reporting score was a measure of completeness of information detailed in media articles as scored by a 15-point scoring instrument. The social media score represented the ubiquity of social media presence referencing 17 practice-changing clinical trials in cancer as determined by the American Society of Clinical Oncology in its annual report, entitled Clinical Cancer Advances 2012; social media score was calculated from Twitter, Facebook, and Google searches. The academic citation score comprised total citations from Google Scholar plus the Scopus database, which represented the academic impact per clinical cancer advance. Results. From 170 media articles, 107 (63%) had sufficient data for analysis. Cohen's kappa coefficient demonstrated reliability of the media reporting score instrument with a coefficient of determination of 94%. Per the media reporting score, information was most complete from industry, followed by cancer websites, newspapers, and cable news. The most commonly omitted items, in descending order, were study limitations, exclusion criteria, conflict of interest, and other. The social media score was weakly correlated with academic citation score. Conclusion. Media outlets appear to have set a low bar for coverage of many practice-changing advances in oncology, with reports of scientific breakthroughs often omitting basic study facts and cautions, which may mislead the public. The media should be encouraged to use a standardized reporting template and provide accessible references to original source information whenever feasible.
引用
收藏
页码:269 / 278
页数:10
相关论文
共 50 条
  • [41] Demographic reporting and language exclusion in gynecologic oncology clinical trials
    Lee, Sarah S.
    Dinicu, Andreea I.
    Arthurs, Likolani
    Shields, Danielle
    Pothuri, Bhavana
    Lightfoot, Michelle D. S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2023, 230 (01) : E1 - E14
  • [42] The need for adverse effects reporting standards in oncology clinical trials
    Trotti, A
    Bentzen, SM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 19 - 22
  • [43] Practice changing cervical cancer clinical trials
    Pothuri, Bhavana
    Eskander, Ramez N.
    Randall, Leslie M.
    O'Malley, David M.
    Slomovitz, Brian
    Moore, Kathleen N.
    Herzog, Thomas J.
    Coleman, Robert L.
    Copeland, Larry J.
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2022, 165 (03) : 410 - 412
  • [44] Worldwide Diversity and Demographic Reporting in Ocular Oncology Clinical Trials
    Ali, Arsalan Akbar
    Bui, Tommy
    Patel, Prem
    Patel, Parth
    Uner, Ogul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [45] Adverse event reporting in oncology clinical trials - lost in translation?
    Sivendran, Shanthi
    Galsky, Matthew D.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 893 - 896
  • [46] Under-reporting of research biopsies in clinical trials in oncology
    Parseghian, Christine M.
    Raghav, Kanwal
    Yao, James
    Ellis, Lee M.
    Tam, Alda
    Overman, Michael J.
    CANCER RESEARCH, 2017, 77
  • [47] A CLINICAL PRACTICE PERSPECTIVE ON PUBLISHING IN ONCOLOGY NURSING
    Gobel, Barbara Holmes
    SEMINARS IN ONCOLOGY NURSING, 2018, 34 (04) : 386 - 392
  • [48] Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group Collaboration
    Giralt, Sergio
    McCarthy, Philip L.
    Anderson, Kenneth C.
    Carter, Shelly L.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Laport, Ginna G.
    Stadtmauer, Edward A.
    Pasquini, Marcelo C.
    Horowitz, Mary M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (06) : 858 - 859
  • [49] Do participants in major, practice-changing breast cancer trials reflect the breast cancer patient population?
    Shaun Treweek
    Ruth Dryden
    Colin McCowan
    Alison Harrow
    Alastair Thompson
    Trials, 14 (Suppl 1)
  • [50] Evaluating generalizability of practice-changing randomized clinical trials in non-small cell lung cancer using machine learning-based in-silico trials
    Orcutt, Xavier
    Mamtani, Ronac
    Sondhi, Arjun
    Cohen, Aaron B.
    Parikh, Ravi Bharat
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)